{"id":"teneli-teneli-su","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5303414","moleculeType":null,"molecularWeight":"442.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teneli inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones (GLP-1 and GIP). By preventing incretin degradation, the drug prolongs their activity, leading to glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion. The 'SU' component likely refers to combination with a sulfonylurea agent for enhanced glycemic control.","oneSentence":"Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:03.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in combination with sulfonylurea)"}]},"trialDetails":[{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13834,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MP-513","Amaryl","glimepiride"],"phase":"phase_3","status":"active","brandName":"Teneli / Teneli + SU","genericName":"Teneli / Teneli + SU","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teneligliptin (Teneli) is a medication used in combination with sulfonylurea (SU) to treat Type 2 Diabetes Mellitus. This combination was studied in a Phase III clinical trial (NCT00974090) to evaluate its efficacy and safety in Japanese patients with Type 2 Diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}